A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder	Recruiting	Phase 2	2024-02-28		NCT06155396

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
RemeGen Co., Ltd.	36

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Beijing Obstetrics and Gynecology Hospital ,Capital Medical University	Beijing	China	1
Chongqing University Cancer Hospital	Chongqing	China	54
Fudan University Shanghai Cancer Center	Shanghai	China	257
Guangxi Tumor Hospital	Nanning	China	1
Hunan Cancer Hospital	Changsha	China	27
Jiangxi Maternal and Child Health Hospital	Nanchang	China	1
Liaoning Cancer Hospital & Institute	Shenyang	China	10
Shandong Cancer Hospital & Institute	Jinan	China	3
The First Affiliated Hospital of Bengbu Medical College	Bengbu	China	8
Tianjin Medical University Cancer Institute and Hospital	Tianjin	China	4
Yunnan Cancer Hospital	Kunming	China	44
Zhejiang Cancer Hospital	Hangzhou	China	34